Precision Biosciences (DTIL) Prepaid Assets (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Prepaid Assets of $6000.0 for Q1 2026, down 99.87% year-over-year from $4.6 million in Q1 2025, and down 99.81% quarter-over-quarter from $3.1 million in Q4 2025.
Precision Biosciences (DTIL) Prepaid Assets (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Prepaid Assets for 9 consecutive years, with $6000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 99.87% year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $6000.0 (down 99.87% YoY), while the FY2025 annual figure was $3.1 million, down 51.72% from the prior year.
- Prepaid Assets eased to $6000.0 in Q1 2026 per DTIL's latest filing, from $3.1 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $17.1 million in Q1 2022 and bottomed at $6000.0 in Q1 2026.
- Historically, Prepaid Assets has averaged $5.2 million across 5 years, with a median of $4.6 million in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets surged 48642.86% — and 2026, when it tumbled 99.87%.
- Precision Biosciences' Prepaid Assets stood at $6.0 million in 2022, then retreated by 0.8% to $6.0 million in 2023, then rose by 7.76% to $6.4 million in 2024, then slumped by 51.72% to $3.1 million in 2025, then slumped by 99.81% to $6000.0 in 2026.
- Business Quant data shows DTIL's Prepaid Assets at $6000.0 in Q1 2026, $3.1 million in Q4 2025, and $848000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 3.11 Mn |
| Sep 30, 2025 | 848,000.00 |
| Jun 30, 2025 | 427,000.00 |
| Mar 31, 2025 | 4.59 Mn |
| Dec 31, 2024 | 6.44 Mn |
| Sep 30, 2024 | 471,000.00 |
| Jun 30, 2024 | 790,000.00 |
| Mar 31, 2024 | 128,000.00 |
| Dec 31, 2023 | 5.98 Mn |
| Sep 30, 2023 | 8.08 Mn |
| Jun 30, 2023 | 503,000.00 |
| Mar 31, 2023 | 8.42 Mn |
| Dec 31, 2022 | 6.03 Mn |
| Sep 30, 2022 | 12.29 Mn |
| Jun 30, 2022 | 12.63 Mn |
| Mar 31, 2022 | 17.06 Mn |
| Dec 31, 2021 | 169,000.00 |
| Sep 30, 2021 | 898,000.00 |